Clinical Trial Update: A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating anti-PD-1 combinations of D-CIK immunotherapy with axitinib in metastatic renal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cancer Metastasis
• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• D-CIK Immunotherapy (D-CIK immunotherapy (dendritic cell and cytokine-induced killer cells))

Snippet

Sponsor: Sun Yat-sen University | Conditions: Renal Cancer Metastatic | Phase 2 | Status: UNKNOWN